{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:47:58Z","timestamp":1790664478584,"version":"4.1.0"},"reference-count":70,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutics and Clinical Risk Management"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.2147\/tcrm.2007.3.1.107","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T20:52:55Z","timestamp":1182286375000},"page":"107-118","source":"Crossref","is-referenced-by-count":23,"title":["Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom"],"prefix":"10.2147","volume":"3","author":[{"given":"Peter","family":"Layer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kreiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"p_1_975","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00003088-200241130-00002","volume":"41","author":"Appel-Dingemanse S.","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"p_2_976","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/107424840200700202","volume":"7","author":"Barbey JT","year":"2002","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"p_3_977","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2036.2004.02032.x","volume":"20","author":"Bardhan KD","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"p_4_978","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1155\/2003\/532138","volume":"17","author":"Bijkerk CJ","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"p_5_979","first-page":"S7","volume":"97","author":"Brandt LJ","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"p_6_980","first-page":"1361","volume":"351","author":"Brinker AD","year":"2004","journal-title":"N Engl J Med"},{"key":"p_7_981","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2982.2005.00645.x","volume":"17","author":"Camilleri M.","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"p_8_982","first-page":"T1139","volume":"128","author":"Chey W","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"p_9_983","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/13543784.14.2.185","volume":"14","author":"Chey WD","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"p_10_984","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.013"},{"key":"p_11_985","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01449.x"},{"key":"p_12_986","unstructured":"[CPMP] European Committee for Medicinal Products for Human Use. 2003. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome [online]. Accessed on . URL: http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/078597en.pdf."},{"key":"p_13_987","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjp.0705762","volume":"141","author":"Crowell MD.","year":"2004","journal-title":"Br J Pharmacol"},{"key":"p_14_988","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01103.x"},{"key":"p_15_989","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1111\/j.1572-0241.2003.08548.x","volume":"98","author":"Dunger-Baldauf C","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"p_16_990","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S0002-9270(02)05326-1","volume":"97","author":"Earnest D","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"p_17_991","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.321.7256.259","volume":"321","author":"Ferriman A.","year":"2000","journal-title":"BMJ"},{"key":"p_18_992","doi-asserted-by":"crossref","first-page":"A752","DOI":"10.1016\/S0016-5085(98)83079-5","volume":"114","author":"Fioramonti J","year":"1998","journal-title":"Gastroenterology"},{"key":"p_19_993","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0002-9270(03)01585-5","volume":"98","author":"Fisher R","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"p_20_994","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1572-0241.2004.30301.x","volume":"99","author":"Fisher R","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"p_21_995","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0149-2918(02)85143-8","volume":"24","author":"Frank L","year":"2002","journal-title":"Clin Ther"},{"key":"p_22_996","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2036.1999.00002.x-i2","volume":"13","author":"Gershon MD.","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"p_23_997","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2004.02180.x","volume":"20","author":"Gershon MD.","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"p_24_998","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"Gralnek IM","year":"2000","journal-title":"Gastroenterology"},{"key":"p_25_999","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70203-3"},{"key":"p_26_1000","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000007593","volume":"60","author":"Hahn B","year":"1999","journal-title":"Digestion"},{"key":"p_27_1001","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1365-2036.2003.01499.x","volume":"17","author":"Hasler WL","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"p_28_1002","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00002018-200427090-00001","volume":"27","author":"Hasler WL","year":"2004","journal-title":"Drug Safety"},{"key":"p_29_1003","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","volume":"17","author":"Hungin AP","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"p_30_1004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","volume":"21","author":"Hungin AP","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"p_31_1005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-3565(24)37929-7","volume":"288","author":"Jin JG","year":"1999","journal-title":"Pharmacol Experimental Ther"},{"key":"p_32_1006","doi-asserted-by":"crossref","unstructured":"Kalbag J, Migoya E, Osborne S, etal 2000. Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects. Gastroenterology, 118(Suppl 2 Pt 2):A71179.","DOI":"10.1016\/S0016-5085(00)80542-9"},{"key":"p_33_1007","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.671"},{"key":"p_34_1008","first-page":"40","volume":"15","author":"Kozma CM","year":"2002","journal-title":"Manag Care Interface"},{"key":"p_35_1009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000087049","volume":"71","author":"Layer P","year":"2005","journal-title":"Digestion"},{"key":"p_36_1010","doi-asserted-by":"crossref","unstructured":"Ledford P, On N, Ligueros-Saylan M, etal 2000. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Gastroenterology, 118(Suppl 2):A1184 (Abstract 5445).","DOI":"10.1016\/S0016-5085(00)80565-X"},{"key":"p_37_1011","first-page":"266","volume":"94","author":"Lefkowitz M","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"p_38_1012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02267.x"},{"key":"p_39_1013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1368-5031.2005.00744.x","volume":"60","author":"Malagelada JR.","year":"2006","journal-title":"Int J Clin Pract"},{"key":"p_40_1014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05986.x"},{"key":"p_41_1015","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"p_42_1016","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00042737-200212000-00007","volume":"14","author":"Muller-Lissner S","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"p_43_1017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02294.x","volume":"21","author":"Muller-Lissner S","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"p_45_1018","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01372.x"},{"key":"p_46_1019","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310006748"},{"key":"p_47_1020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2982.2005.00650.x","volume":"17","author":"Patel SM","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"p_48_1021","first-page":"M994","volume":"128","author":"Patrick DL","year":"2005","journal-title":"Gastroenterology"},{"key":"p_49_1022","first-page":"280","volume":"7","author":"Pfannkuche HJ","year":"1995","journal-title":"Neurogastroenterol Motil"},{"key":"p_50_1023","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70251-4"},{"key":"p_51_1024","doi-asserted-by":"crossref","unstructured":"Quartero A, Meineche-Schmidt V, Muris J, etal 2005. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev, 2:CD003460.","DOI":"10.1002\/14651858.CD003460.pub2"},{"key":"p_52_1025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02577.x","volume":"22","author":"Reilly MC","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"p_53_1026","unstructured":"Sabate J, Bouhassira D, Poupardin C, etal 2005. Antinociceptive effect of tegaserod in female IBS constipated patients. Gastroenterology, 128(Suppl 2):A-468."},{"key":"p_54_1027","doi-asserted-by":"crossref","first-page":"A643","DOI":"10.1016\/S0016-5085(99)70186-1","volume":"116","author":"Schikowski A","year":"1999","journal-title":"Gastroenterology"},{"key":"p_55_1028","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.1999.01440.x","volume":"94","author":"Schmulson M","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"p_56_1029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2036.2004.01864.x","volume":"19","author":"Schoenfeld P.","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"p_57_1030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.gtc.2005.02.002","volume":"34","author":"Schoenfeld P.","year":"2005","journal-title":"Gastroenterol Clin North Am"},{"key":"p_58_1031","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11.1684"},{"key":"p_59_1032","unstructured":"Singh G, Mithal A, Kahler K, etal 2004. Patients with irritable bowel syndrome have a high risk of developing colon ischemia. Gut, 53(Suppl VI):A66."},{"key":"p_60_1033","first-page":"G287","volume":"116","author":"Stoner MC","year":"1999","journal-title":"Gastroenterology"},{"key":"p_61_1034","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"p_62_1035","first-page":"1143","volume":"45","author":"Thompson WG","year":"1999","journal-title":"Gut"},{"key":"p_63_1036","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01347.x"},{"key":"p_64_1037","unstructured":"Uscanga-Dominguez L, Cohen Munoz V. 2003. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C). Gastroenterology, 124(Suppl 1):A-571."},{"key":"p_65_1038","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0210-5705(03)70470-1","volume":"27","author":"Valenzuela J","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"p_66_1039","first-page":"1269","volume":"29","author":"Vickers AEM","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"p_67_1040","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(01)00485-5"},{"key":"p_68_1041","first-page":"P108","volume":"65","author":"Zhou H","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"p_69_1042","doi-asserted-by":"crossref","unstructured":"Zhou H, Walter Y, Hubert M, etal 2000. Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects. Gastroenterology, 118(Suppl 2 Pt 2):A5539.","DOI":"10.1016\/S0016-5085(00)80659-9"},{"key":"p_70_1043","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012625"},{"key":"p_71_1044","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010979"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:44:50Z","timestamp":1737110690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/tegaserod-in-the-treatment-of-irritable-bowel-syndrome-ibs-with-consti-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.2147\/tcrm.2007.3.1.107"],"URL":"https:\/\/doi.org\/10.2147\/tcrm.2007.3.1.107","relation":{},"ISSN":["1176-6336"],"issn-type":[{"value":"1176-6336","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}